A new Monash Technology Precinct accelerator focussing on cardiovascular, kidney and metabolic diseases will help transform medical innovation ideas into reality.
Monash Velos Accelerator will facilitate the translation and commercialisation of clinical research, health technologies, new care models, drug discovery, and biomedical engineering.
Enabled by $17.5 million through the Victorian Higher Education State Investment Fund, Velos is the state’s first facility of its kind. It will embed commercialisation capabilities in the heart of academia and the health sector.
The accelerator is opposite the Victorian Heart Hospital (VHH), which incorporates the Monash Victorian Heart Institute (VHI), and within the Monash Technology Precinct in Australia.
It will unite clinicians, researchers, and industry partners, while leveraging world-class expertise and infrastructure at the VHH, VHI and broader Monash innovation ecosystem to foster stronger cross-sector collaboration and expedite innovation.
Early Velos tenants will include the team developing MAVERIC, a Monash University program that is transforming Australia’s sovereign Artificial Intelligence (AI) research capability with a $60 million investment to build and operate an advanced AI supercomputer. This will place the University as a leader in AI-driven research within the international higher education and research sector.
VHH and VHI director Professor Stephen Nicholls said Velos would establish a community of forward-thinking healthcare professionals and empower them and their organisations to advance the future of medical technology and research.
